Pearl River Delta Sets Up Biopharm R&D Supply Chain Alliance
This article was originally published in PharmAsia News
Executive Summary
Guangzhou Biological Engineering Center, together with more than 60 biopharmaceutical enterprises and academic institutions in Pearl River Delta, recently formed a biopharmaceutical R&D supply chain alliance. The grouping aims to gain more purchasing clout by establishing a mutually beneficial relationship with local and overseas suppliers through integrated supply chain resources to increase efficiency and convenience. The alliance will set up a biopharmaceutical online portal for R&D materials purchase and develop it into an advanced e-business platform that spurs local innovation. GBEC has approached many R&D teams as purchasers and disclosed that more than 150 suppliers of international biopharmaceutical devices, consumables and reagents have indicated their interest in joining the alliance. (Click here for more - Chinese Language)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.